Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. United States
  4. Nasdaq
  5. Novavax, Inc.
  6. News
  7. Summary
    NVAX   US6700024010

NOVAVAX, INC.

(NVAX)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Novavax : Cantor Fitzgerald Adjusts Novavax PT to $272 From $217, Maintains Overweight Rating

06/15/2021 | 08:59am EST


ę MT Newswires 2021
All news about NOVAVAX, INC.
12/07Novavax COVID Vaccine May Be Approved in 'Very Near Future,' European Medicines Agency ..
MT
12/07European Medicines Agency to Approve Novavax COVID-19 Vaccine In 'Very Near Future;' Sh..
MT
12/07Novavax COVID-19 vaccine could be approved very soon, says EMA chief
RE
12/07Head of eu drugs regulator says novavax vaccine could be authorised in the near future
RE
12/06AstraZeneca, Pfizer-BioNTech's COVID-19 Jabs Work Well With Moderna Shot, UK Study Says
MT
12/06Mixing Pfizer, AstraZ COVID-19 shots with Moderna gives better immune response -UK stud..
RE
12/03Novavax Statement on Omicron Variant Response
AQ
12/02INSIDER SELL : Novavax
MT
12/02Novavax Begins Development of Omicron-Specific Vaccine, Manufacturing Expected in Janua..
MT
12/02What COVID-19 vaccine and drug makers have to say about Omicron
RE
More news
Analyst Recommendations on NOVAVAX, INC.
More recommendations
Financials (USD)
Sales 2021 1 396 M - -
Net income 2021 -905 M - -
Net cash 2021 756 M - -
P/E ratio 2021 -15,1x
Yield 2021 -
Capitalization 13 825 M 13 825 M -
EV / Sales 2021 9,36x
EV / Sales 2022 2,46x
Nbr of Employees 792
Free-Float 98,5%
Chart NOVAVAX, INC.
Duration : Period :
Novavax, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends NOVAVAX, INC.
Short TermMid-TermLong Term
TrendsNeutralNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 6
Last Close Price 182,85 $
Average target price 260,60 $
Spread / Average Target 42,5%
EPS Revisions
Managers and Directors
Stanley C. Erck President, Chief Executive Officer & Director
James Patrick Kelly Chief Financial Officer, Treasurer & Executive VP
James F. Young Chairman
Gregory M. Glenn President-Research & Development
Biegie Lee Chief Information Officer & Senior Vice President
Sector and Competitors
1st jan.Capi. (M$)
NOVAVAX, INC.63.98%13 825
MODERNA, INC.170.27%114 479
LONZA GROUP AG24.16%58 572
IQVIA HOLDINGS INC.50.86%51 638
SEAGEN INC.-16.39%26 777
CELLTRION, INC.-43.31%23 611